Asosiy kontentga oʻtish
Boshqa

Abstract 11322: Maternal Triglyceride-Glucose Index and Adverse Pregnancy Outcomes: Association and Prognostic Performance in a Systematic Review and Meta-Analysis

Carolina FelippeDept of Medicine, Unigranrio Afya Med Sch, Rio de Janeiro, Brazil, Rio de Janeiro, BrazilMaria LemosKurah Women’s Health Institute, Rio de Janeiro, BrazilREBECA FERREIRA SOUZAFarida NamozovaTashkent Med Academy, Tashkent, UzbekistanMariano Gallo RuelasSch of Public Health, Imperial College London, London, United Kingdom, London, United KingdomAna Clara Pimenta ServidoniFaculdade Santa Marcelina, Sao Paulo, BrazilParvaneh RastgouYale Sch of Medicine, New Haven, CTsinrraim ruizFederal Univ of São Paulo (UNIFESP), São Paulo, BrazilGabriela MaraneziSanta Marcelina College (FASM), Sao Paulo, BrazilAna Paula BeckAlbert Einstein Israeli Institute of Education and Rsch, Albert Einstein Israeli Hosp, São Paulo, BrazilEduardo SantanaDept of Women's Health, Albert Einstein Israeli Sch of Health Sciences (FICSAE, São Paulo, Brazil
2026en

Ochiq kirish: yoʻq

ABI

Annotatsiya

Background: Pregnancy is marked by metabolic adaptation, and progressive insulin resistance contributes to maternal and fetal complications. The triglyceride-glucose (TyG) index, derived from fasting triglyceride and glucose levels, is a practical surrogate of insulin resistance, but its prognostic role during pregnancy remains uncertain. Objective: To examine the association between maternal TyG levels and adverse pregnancy outcomes and summarize prognostic performance for selected obstetric complications. Methods: We searched PubMed, Embase, and Cochrane databases from inception to May 2026 for studies evaluating TyG as a prognostic tool during pregnancy. We computed odds ratios (ORs) for binary outcomes, with 95% confidence intervals (CI). Diagnostic accuracy measures and summary receiver operating characteristic (SROC) analyses were also calculated. Results: Twenty-one studies involving 195,787 pregnant women were included. Studies that assessed TyG in the first trimester included 162,237 women (82.9% of the total population), corroborating its potential applicability as an early-pregnancy risk-stratification tool. Higher TyG levels were associated with gestational diabetes mellitus (OR 2.66; 95% CI 2.21-3.20; Figure 1A), preeclampsia (OR 2.31; 95% CI 1.60-3.33; Figure 1B), gestational hypertension (OR 1.73; 95% CI 1.44-2.09), macrosomia (OR 1.61; 95% CI 1.20-2.17), LGA (OR 1.60; 95% CI 1.44-1.78), and preterm birth (OR 1.47; 95% CI 1.26-1.72). Prognostic performance was moderate for composite adverse outcomes (pooled sensitivity 77.2% [95% CI, 64.6-86.3], pooled specificity 57.9% [95% CI, 38.9-74.8], and an AUC of 0.71 [95% CI, 0.61-0.81; Figure 2], with a DOR of 4.74 [95% CI, 2.99-7.53]), with modest-to-moderate performance for macrosomia (AUC 0.70) and GDM (AUC 0.64). No significant subgroup differences were found by gestational timing. Conclusions: Elevated maternal TyG levels were associated with multiple adverse pregnancy outcomes and demonstrated moderate prognostic performance. As a low-cost and widely available biomarker, TyG may serve as a practical first-trimester tool for cardiometabolic risk stratification and identification of high-risk pregnancies, warranting further prospective evaluation.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba